Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 2Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Neoplasms 1Lymphoma, Mantle-Cell 1Lymphoma 1Hematologic Neoplasms 1Hematologic Diseases 1Blood Protein Disorders 1

Interventions

Cyclophosphamide 19fludarabine 18Tacrolimus 10Whole-Body Irradiation 9Mycophenolic Acid 8venetoclax 7fludarabine phosphate 7Sirolimus 7Azacitidine 7Mesna 5Dexamethasone 5Bortezomib 5Rituximab 4Methotrexate 4Busulfan 4daratumumab 3Stem Cell Transplantation 3Peripheral Blood Stem Cell Transplantation 3Nivolumab 3Melphalan 3Lenalidomide 3Filgrastim 3Cytarabine 3Biopsy 3Alemtuzumab 3AP 1903 reagent 3pomalidomide 2merphos 2isatuximab 2ibrutinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Hematologic Neoplasms × ricolinostat × Clear all
NCT02091063 2024-08-06

ACY-1215 for Relapsed/Refractory Lymphoid Malignancies

Columbia University

Phase 1/2 Terminated
23 enrolled 6 charts
LymphoidOther hematologic neoplasm

Lymphoma, Hematologic Neoplasms, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡